



Published in final edited form as:

Am J Nephrol. 2015 ; 41(0): 305–312. doi:10.1159/000430922.

Renal Function and Long-term Decline in Cognitive Function: The Baltimore Longitudinal Study of Aging

Stephen L. Seliger, MD MS¹, Carrington R. Wendell, PhD^{2,3}, Shari R. Waldstein, PhD^{2,4,5},
Luigi Ferrucci, MD PhD³, and Alan B. Zonderman, PhD³

¹Division of Nephrology, Department of Medicine, University of Maryland School of Medicine

²Department of Psychology, University of Maryland, Baltimore County

³Intramural Research Program, National Institute of Aging, NIH

⁴Division of Gerontology & Geriatric Medicine, Department of Medicine, University of Maryland School of Medicine

⁵Geriatric Research Education and Clinical Center, Baltimore VA Medical Center

Abstract

Background—Renal disease has been associated with greater risk of dementia and greater cognitive impairment. However, the relationship of lower renal function with long-term decline in specific domains of cognitive function remains unclear among community-dwelling, nondemented individuals.

Methods—Stroke- and dementia-free participants (n=2,116) were enrolled in the Baltimore Longitudinal Study of Aging (BLSA), a community-based, prospective, longitudinal study. Renal function was estimated by the inverse of serum creatinine adjusted for age, sex, and race, and (in sensitivity analyses) GFR estimated using the MDRD formula. Outcome measures were changes in scores on 6 cognitive tests encompassing a range of cognitive functions, measured at 2 year intervals. Mixed-effects regression models examined the longitudinal relations of renal function with cognitive functions, adjusting for demographics, co-morbidity, and other potential confounders.

Results—Mean age at initial testing was 53.9 (SD=17.1) years, 94 (4.4%) participants had eGFR<60 cc/min/1.73m², and 18.5% had at least one co-morbidity. With increasing age, longitudinal increases in creatinine concentrations were associated with more rapid decline in performance on several cognitive measures, including the learning slope of the California Verbal Learning Test (CVLT; a test of verbal learning; p<.01) and the Benton Visual Retention Test (BVRT), a test of visual memory (p<.01). Associations were similar for changes in eGFR_{MDRD}, which was also associated with rate of decline in verbal memory.

Conclusion—In a community-based adult population, declines in renal function independently associated with greater long-term declines in visual memory and verbal memory and learning.

Corresponding Author: Stephen L. Seliger, MD, 22 S. Greene St N3W143, Baltimore, MD 21201; Phone: 410-328-5720; Fax: 410-605-7849; sseliger@medicine.umaryland.edu.

Conflict of Interest: The authors have no conflicts of interest to disclose.

Keywords

Kidney function; creatinine; estimated glomerular filtration rate; cognitive function; neuropsychology; longitudinal trajectories

Introduction

Cognitive function declines with age, but the rate of decline varies greatly among individuals. The presence of cardiovascular risk factors such as hypertension, diabetes, and dyslipidemia may explain some of the variability in age-related decline, and in particular may accelerate the rate of decline or the risk of incident cognitive impairment [1,2]. Chronic Kidney Disease (CKD) is a highly prevalent condition [3] that increases with age and is strongly related to cardiovascular risk [4], including risk of cerebrovascular disease [5]. A major role for CKD in accelerating cognitive decline with aging is therefore plausible, although prior studies testing this hypothesis have been limited.

Among patients with end-stage renal disease (ESRD) on maintenance dialysis, several cross-sectional studies have reported a high prevalence of cognitive impairment and lower average cognitive function when compared to controls with preserved renal function [6,7]. In study samples from the general population and from patients with selected co-morbidities, lower average neurocognition was also observed in association with mild-moderate decrements of renal function, suggesting that impairments are not limited to those with severe azotemia [8-10]. However, prior studies were limited by either a cross-sectional design [8,9,11], or by the use of global mental status measures (e.g., the Mini Mental State Examination; MMSE) [10,12], which has limited sensitivity and specificity in detecting age-related changes in different cognitive functions with aging.

The primary aim of this study was to determine the association of changes in renal function with longitudinal changes in specific domains of cognitive function among community-dwelling stroke-free and dementia-free adults, using repeated assessments of multiple cognitive functions performed in the Baltimore Longitudinal Study of Aging (BLSA). We hypothesized that declining renal function would be associated with more rapid decline in cognitive function.

Materials and Methods

Study Sample

The BLSA is a prospective cohort study of community-dwelling participants conducted by the National Institute on Aging's Intramural Research Program since 1958. Approximately every two years, participants visit the National Institute on Aging in Baltimore, MD for medical, psychological, and cognitive testing. Beginning in 1986, a more extensive neuropsychological test battery was administered at each visit to participants 60 years and older. The majority of tests for which data were analyzed in this study were therefore available after 1986. The BLSA uses continuous enrollment procedures; thus, the years of enrollment and number of total visits differ among participants. In addition, for any given participant the number of measures for each cognitive test may differ, depending on when a

patient entered the study and in what year a given test was introduced to the test battery. For the purposes of the present analysis, participants with prior or incident stroke or a prior or incident diagnosis of dementia were excluded.

Institutional Review Board approval was obtained from the Johns Hopkins Bayview Medical Center prior to 2002, and the MedStar Research Institute after 2002. All participants provided written informed consent. Data analyses were approved by the Institutional Review Board of the University of Maryland, Baltimore County.

Neuropsychological Tests

At each BLSA visit, a neuropsychological test battery was administered by trained psychometricians. The Digits Forward and Digits Backward portions of the Wechsler Adult Intelligence Scale-Revised (WAIS-R) assessed attention and concentration/working memory. Verbal learning and memory were assessed with the California Verbal Learning Test (CVLT), with derived scores including short and long free recall and the learning slope. Visual memory was assessed using the Benton Visual Retention Test (BVRT). The Trail Making Test Parts A & B assessed attention, visuomotor scanning, perceptuo-motor speed, and mental flexibility (an executive function). Other tests included Letter and Category Fluency (phonemic and semantic association fluency, respectively, and executive function) and the Boston Naming Test (confrontation naming). The Mini Mental State Exam (MMSE) was administered as a screening test for general cognition; MMSE scores were not considered an outcome variable in this analysis due to the narrow range of scores observed.

Primary Predictor Variable

The primary measure of renal function was the inverse of the serum creatinine (1/SCr). The decision to use 1/SCr rather formula-derived estimates of GFR was motivated by the use of mixed-regression models to estimate associations with change in cognitive function (see “Statistical Analysis”, below). The primary measures of association in these mixed-effects models are the coefficients for the interaction between age and renal function. Therefore, including MDRD- or CKD-Epi-estimated GFR – which itself involves an interaction between age and 1/SCr – as the primary measure of renal function would result in a model with significant challenges to interpretation. However, by accounting for factors other than GFR which influence creatinine levels – age, gender, race, body mass – as independent covariates in the mixed model, the model coefficients for Age*1/Scr can be reasonably interpreted as primarily representing the association of renal filtration function with changes in cognitive function. However, given the widespread use of estimated GFR in both clinical care and epidemiologic study of renal disease, we performed secondary analyses replacing 1/SCr with eGFR estimated using the 4-variable MDRD equation as the primary predictor variable.

Covariates

Age was scaled per decade, and education was measured in years. Mean arterial pressure was calculated as $(2*DBP+SBP)/3$ from seated blood pressure measures at each study visit. Body mass index (BMI) was calculated as the ratio of weight (in kilograms) to height (in meters) squared, both measured with a clinical calibrated scale. Medication use including

anti-hypertensives, non-steroidal anti-inflammatory drugs, and aspirin and was coded as yes/no at each visit. Laboratory measurements were performed at each study visit at the clinical laboratories of the NIA. Laboratory data abstracted for the present analysis included hemoglobin and creatinine. Because the frequency of specific individual co-morbidities was low in this relatively healthy cohort, we used a co-morbidity index score representing the number of different co-morbid conditions (identified by the study physician at each visit from medical history) including coronary artery disease, myocardial infarction, congestive heart failure, peripheral arterial disease, transient ischemic attack, and diabetes mellitus. Cigarette smoking was characterized as current versus former or never.

Statistical Analysis

All statistical analyses were performed using SAS version 9.2 (Cary, NC). Mixed-effects linear regression models were developed to examine the longitudinal relations between renal function and cognitive functions. Mixed-effects models are the preferred method for analyzing data in which repeated outcome measures are assessed at non-uniform intervals among individuals (i.e., unbalanced data). They allow for both fixed and random terms, accounting for correlation of repeated measures within individuals, and are appropriate in the setting of variable lengths of follow-up among individual participants. Both renal and cognitive function were measured at each BLSA visit; analyses thus examine coincident trajectories of renal and cognitive function over time.

In order to maximize the information associated with each neuropsychological test, separate mixed models were developed for each test. Adjustment covariates were the same for each neurocognitive outcome and were selected a priori based on factors which could plausibly relate to cognitive decline, based on prior studies of the BLSA [13] and/or were plausibly related to renal function and serum creatinine levels, and included: age, sex, education, mean arterial pressure, hemoglobin, smoking, co-morbidity score, NSAID use, and use of aspirin. All covariates other than sex were treated as time-varying. In sensitivity analyses, additional adjustment was made for race, body mass, and the use of anti-hypertensive medications.

Age was also modeled as a random term to index time [14]. The practice of using age as a metric for time is recommended by McArdle and Bell[15] for instances in which a study lacks a natural baseline due to randomness of time of study entry, which is the case in the BLSA. The distribution of participants over time is regarded as a sample of performance opportunities across ages. With sufficient numbers of participants over a sufficiently broad range of ages, we can examine the overall differences in rates of change in time-varying effects. As a result, individuals with only a single measurement are able to contribute information to the analyses.

Models included both main and interactive, longitudinal terms of interest. Significant main effects of renal function indicate that the cognitive outcome (collapsed across all available testing sessions) is associated with overall differences in renal function, regardless of longitudinal change. Longitudinal change in the cognitive outcome associated with renal function is indicated by the interaction term of renal function and age. The latter reflects age-related differences in cognitive decline as a function of prospectively-assessed change in renal function. P-values less than .05 were considered statistically significant.

Results

Study Participants

After exclusion of participants with stroke and/or dementia (n=172), a total of 2,116 participants received at least one cognitive test. The Benton Visual Retention Test (BVRT) was the test for which the largest participant sample provided data. The characteristics of the participants at first BVRT administration are shown in Table 1. A total of 94 (4.4%) participants had an estimated GFR <60 cc/min/1.73m². The number of participants contributing data for each cognitive test and the number of test administrations per individual is shown in Supplementary Table 1 online. Each test was administered over a median of 4-5 visits per individual over a mean 7.7 years.

Association of 1/SCr and cognitive functional decline

A significant age × 1/SCr interaction was observed for the CVLT learning slope (b=0.126, p=.008). Figure 1a shows the model-based predicted CVLT score as a function of time and serum creatinine level; with increasing levels of creatinine, the rate of decline of test performance is more rapid. A significant longitudinal age × 1/SCr interaction was also observed for the Benton Visual Retention Test; however, the association differed significantly between men and women (test for interaction by sex, p=.002). Figures 1b and 1c show the model-based estimated scores for the BVRT as a function of age and serum creatinine, for both men (b) and women (c). The rate of decline in performance on the BVRT was greater with increasing levels of creatinine, but the association was more pronounced among men than women. No significant independent associations of 1/SCr with rate of change in the other cognitive tests scores were observed, although performances on most tests were observed to decline over time (Table 2).

No significant departure from linearity was observed for the longitudinal associations of 1/SCr with cognitive function. Additional adjustment for race, body mass, and use of anti-hypertensive medications (the latter two as time-varying covariates) did not materially change the results. Specifically, there remained a significant 1/SCr*age interaction for CVLT learning slope: (p<.05) and for the Benton Visual Retention Test (p<.01), with a greater association of higher creatinine with age-related decline in the BVRT among men than among women (p<.001 for 1/SCr*age*sex interaction). Likewise, additional adjustment for the assay method for serum creatinine (as a time-varying covariate) did not change the results (supplemental table 2). In an additional sensitivity analysis, we examined whether associations differed after excluding those with prevalent CVD and estimated GFR<60 cc/min/1.73m² at baseline. Results were largely unchanged: a significant age*1/SCr interaction was still observed for the CVLT slope (supplemental table 3) with greater age-related decline with higher serum creatinine levels, and a significant longitudinal age × 1/SCr interaction was observed for the Benton Visual Retention Test, with greater age-related decline with higher SCr levels, and more pronounced associations among men than women. There was a significant age × 1/SCr × sex interaction for performance on the Trails B test; however, there among neither men nor women was the decline in test performance related to serum creatinine, and the interaction was driven largely by 4 influential outlying values.

Secondary analysis: association of eGFR and longitudinal cognitive function changes

Significant associations ($p < .01$) were observed also between eGFR and change in performance on the BVRT and CVLT learning slope, with the direction of the regression coefficients indicating slower decline with higher eGFR (Table 3). Significant ($p < .05$) associations were also observed between higher eGFR and slower declines in performance on the CVLT short- and long-delay free recall, tests of verbal memory. No significant interactions were observed for changes in performance on Digit Span, Letter Frequency or Category frequency tests. For changes on the trail-making test parts A and B, the relationship of eGFR with decline in performance differed significantly ($p < .01$) by gender, but among neither men nor women was the relationship significant.

Discussion

Among community-dwelling stroke- and dementia-free adults followed longitudinally, declining renal filtration was associated with a more rapid decline in the cognitive functions of verbal learning/memory and visual memory, after adjustment for potential demographic and some potentially confounding factors. In contrast, changes in renal function were not associated with a more rapid decline on tests of naming, executive function, language fluency, nor psychomotor speed. These findings are notable in that the study sample was relatively healthy, with only 19% having diabetes or cardiovascular disease. Furthermore, differences in rates of cognitive decline were observed over a relatively modest range of decreased renal function, and among participants without evidence of global cognitive impairment, as evidenced by excluding participants with dementia diagnoses.

Results of our investigation are not directly comparable to prior studies of CKD and cognition given differences in the specific cognitive tests used as well as differences between longitudinal and cross-sectional designs. Nevertheless, among prior studies, lower function in the domains of verbal and visual memory and learning has also been reported in association with end-stage renal disease [6], non-dialysis CKD [16], and lower renal function [11]. The current study suggests that not only do individuals with renal impairment have lower function in verbal and/or visual memory, but they also experience a faster rate of decline in these functions with aging. However, we did not find a relation between declining renal function and more rapid decline on tests of psychomotor speed and complex attention, in contrast to some prior studies which found associations of renal impairment and lower performance in these functional domains. Although most of these studies were cross-sectional, a longitudinal analysis of older adults identified lower renal function as a predictor of more rapid decline in performance of the Digit Symbol Substitution Test, a measure of complex attention and set-shifting [17]. Other functional domains including memory and learning were not assessed in that study.

The factors which explain the associations between reduced renal function and more rapid age-related decline in cognitive functions remain uncertain, although a number of mechanisms have been proposed. For example, patients with renal impairment have associated systemic and cerebral vascular changes. Systemic changes include reduced vascular compliance and greater aortic stiffness, which have been linked to worse cognitive performance in older adults. Within the brain, even modestly lower renal function has been

associated with a greater burden of white matter hyperintensities on cranial imaging [18,19], linked to cognitive impairment. In support of this hypothesis, we have previously reported that moderate renal impairment was associated with a greater long-term risk of incident vascular-type dementia in older adults, even after accounting for co-morbidity [20]. Other potential factors linking renal impairment and disease with cognitive dysfunction include micro-inflammation, oxidative stress, hyperhomocysteinemia, and altered nitric oxide metabolism. However, the causal relations among renal function, cognitive function, and these physiological factors remain uncertain.

The mechanisms underlying the sex difference in relations of renal decline to BVRT decline remain unclear. Visual memory performance is heavily reliant on medial temporal lobe function, and animal research suggests that age-related hippocampal atrophy is more pronounced among males than females [21]. However, the absence of sex differences in associations between renal function and CVLT performance suggests that other factors are involved, given that verbal memory performance is also reflective of hippocampal function.

Limitations of the study include the use of serum creatinine as a renal function marker, which can result in misclassification of true GFR due to inter-individual differences in creatinine generation and tubular secretion. However, results were similar when estimated GFR was used as an alternative renal function marker. The BLSA is a sample of convenience, and does not represent a true community- or population-based study sample. Participants were well educated compared to the general population, and recruited from one geographic location, so the results may not be generalizable to other populations. We cannot exclude the possibility of a type I (false positive) error in the setting of examination of associations with multiple cognitive test outcomes. However, the similarity of results when either 1/SCr or eGFR was used as a renal function marker suggests the observed associations with visual and verbal memory are not due to chance alone. Finally, this study sample did not have measurements of albuminuria, which has also been linked to cognitive dysfunction independently of renal filtration function [22,23]. Strengths of the study include the longitudinal study design, the more extensive cognitive test battery administered, and the evaluation of multiple potential confounders. Simultaneous examination of declines in kidney function in relation to declines in cognitive function represents a unique contribution to the literature, and parallels recent findings involving kidney function decline and prospective cardiovascular risk [24].

Conclusions

In conclusion, among a community-dwelling adult population, modest declines in renal function are associated with a greater decline in verbal memory/learning and visual memory with age, after accounting for differences in demographics and co-morbidity, whereas no associations were observed with decline in other cognitive domains. These findings are notable in the context of a relatively healthy sample (i.e., low-comorbidity), across a modest range of decreased renal function and without cognitive impairment. Future investigation is needed to determine the factors that explain these associations.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding: The National Institute on Aging Intramural Research Program of the National Institutes of Health supported this research.

References

1. Waldstein, SR.; Elias, MF. Neuropsychology of cardiovascular disease. Lawrence Erlbaum Associates; Mahway, NJ: 2001.
2. Waldstein, SR.; Wendell, CR.; Hosey, MH.; Seliger, SL.; Katznel, LI. Cardiovascular disease and neurocognitive function. In: Armstrong, CL.; Morrow, L., editors. Handbook of medical neuropsychology: Applications of cognitive neuroscience. Springer; New York: 2010. p. 69-100.
3. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the united states. JAMA. 2007; 298:2038–2047. [PubMed: 17986697]
4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351:1296–1305. [PubMed: 15385656]
5. Seliger SL, Longstreth WT Jr. Lessons about brain vascular disease from another pulsating organ, the kidney. Stroke. 2008; 39:5–6. [PubMed: 18048859]
6. Murray AM, Tupper DE, Knopman DS, Gilbertson DT, Pederson SL, Li S, Smith GE, Hochhalter AK, Collins AJ, Kane RL. Cognitive impairment in hemodialysis patients is common. Neurology. 2006; 67:216–223. [PubMed: 16864811]
7. Sehgal AR, Grey SF, DeOreo PB, Whitehouse PJ. Prevalence, recognition, and implications of mental impairment among hemodialysis patients. Am J Kidney Dis. 1997; 30:41–49. [PubMed: 9214400]
8. Hailpern SM, Melamed ML, Cohen HW, Hostetter TH. Moderate chronic kidney disease and cognitive function in adults 20 to 59 years of age: Third national health and nutrition examination survey (nhanes iii). J Am Soc Nephrol. 2007; 18:2205–2213. [PubMed: 17554148]
9. Kurella M, Yaffe K, Shlipak MG, Wenger NK, Chertow GM. Chronic kidney disease and cognitive impairment in menopausal women. Am J Kidney Dis. 2005; 45:66–76. [PubMed: 15696445]
10. Kurella Tamura M, Wadley V, Yaffe K, McClure LA, Howard G, Go R, Allman RM, Warnock DG, McClellan W. Kidney function and cognitive impairment in us adults: The reasons for geographic and racial differences in stroke (regards) study. Am J Kidney Dis. 2008; 52:227–234. [PubMed: 18585836]
11. Elias MF, Elias PK, Seliger SL, Narsipur SS, Dore GA, Robbins MA. Chronic kidney disease, creatinine and cognitive functioning. Nephrology Dialysis Transplantation. 2009; 24:2446–2452.
12. Kurella M, Chertow GM, Fried LF, Cummings SR, Harris T, Simonsick E, Satterfield S, Ayonayon H, Yaffe K. Chronic kidney disease and cognitive impairment in the elderly: The health, aging, and body composition study. J Am Soc Nephrol. 2005; 16:2127–2133. [PubMed: 15888561]
13. Wendell CR, Zonderman AB, Metter EJ, Najjar SS, Waldstein SR. Carotid intimal medial thickness predicts cognitive decline among adults without clinical vascular disease. Stroke. 2009; 40:3180–3185. [PubMed: 19644063]
14. Waldstein SR, Giggey PP, Thayer JF, Zonderman AB. Nonlinear relations of blood pressure to cognitive function: The baltimore longitudinal study of aging. Hypertension. 2005; 45:374–379. [PubMed: 15699446]
15. McArdle, J.; Bell, R. An introduction to latent growth models for developmental data analysis. In: TD, L.; KU, S.; J B, editors. Modeling longitudinal and multilevel data: Practical issues, applied approaches, and specific examples. Erlbaum; Mahwah, NJ: 2000.

16. Thornton WL, Deria S, Gelb S, Shapiro RJ, Hill A. Neuropsychological mediators of the links among age, chronic illness, and everyday problem solving. *Psychol Aging*. 2007; 22:470–481. [PubMed: 17874948]
17. Yaffe K, Lindquist K, Shlipak MG, Simonsick E, Fried L, Rosano C, Satterfield S, Atkinson H, Windham BG, Kurella-Tamura M. Cystatin c as a marker of cognitive function in elders: Findings from the health abc study. *Annals of Neurology*. 2008; 63:798–802. [PubMed: 18496846]
18. Ikram MA, Vernooij MW, Hofman A, Niessen WJ, van der Lugt A, Breteler MMB. Kidney function is related to cerebral small vessel disease. *Stroke*. 2008; 39:55–61. [PubMed: 18048865]
19. Seliger SL, Longstreth WT Jr, Katz R, Manolio T, Fried LF, Shlipak M, Stehman-Breen CO, Newman A, Sarnak M, Gillen DL, Bleyer A, Siscovick DS. Cystatin c and subclinical brain infarction. *J Am Soc Nephrol*. 2005; 16:3721–3727. [PubMed: 16236809]
20. Seliger SL, Siscovick DS, Stehman-Breen CO, Gillen DL, Fitzpatrick A, Bleyer A, Kuller LH. Moderate renal impairment and risk of dementia among older adults: The cardiovascular health cognition study. *J Am Soc Nephrol*. 2004; 15:1904–1911. [PubMed: 15213280]
21. Markham JA, McKian KP, Stroup TS, Juraska JM. Sexually dimorphic aging of dendritic morphology in ca1 of hippocampus. *Hippocampus*. 2005; 15:97–103. [PubMed: 15390161]
22. Barzilay JI, Fitzpatrick AL, Luchsinger J, Yasar S, Bernick C, Jenny NS, Kuller LH. Albuminuria and dementia in the elderly: A community study. *Am J Kidney Dis*. 2008; 52:216–226. [PubMed: 18468749]
23. Weiner DE, Bartolomei K, Scott T, Price LL, Griffith JL, Rosenberg I, Levey AS, Folstein MF, Sarnak MJ. Albuminuria, cognitive functioning, and white matter hyperintensities in homebound elders. *Am J Kidney Dis*. 2009; 53:438–447. [PubMed: 19070412]
24. Shlipak MG, Katz R, Kestenbaum B, Siscovick D, Fried L, Newman A, Rifkin D, Sarnak MJ. Rapid decline of kidney function increases cardiovascular risk in the elderly. *J Am Soc Nephrol*. 2009; 20:2625–2630. [PubMed: 19892934]




Figure 1a.
Rate of change in verbal learning (CVLT learning slope), by serum creatinine concentration.




Figure 1b. Change in visual memory (# errors on Benton Visual Retention Test), by serum creatinine concentration – males.




Figure 1c.
Change in visual memory (# errors on Benton Visual Retention Test), by serum creatinine concentration – females

Table 1

Characteristics of study sample at first BLSA visit.

Variable	Mean or Percent	SD
Age, y	53.9	17.1
Age (%)		
17-29	9.8	
20-39	14.5	
40-49	14.5	
50-59	20.8	
60-69	17.6	
79-79	16.4	
80-94	6.1	
Education, y	16.7	2.8
Sex, % male	61.6	
Race, % white	85.5	
MAP, mm Hg	95.7	13.2
Hemoglobin, g/dL	14.5	1.4
Smokers, %	20.0	
NSAID use, %	13.9	
Aspirin use, %	11.5	
Antihypertensive medications, %	16.4	
Comorbidity Index, % >0	18.5	
Diabetes mellitus, %	4.9	
Serum creatinine, mg/dL	0.81	0.22
Estimated GFR, cc/min/1.73m ²	103.2	26.6
eGFR <60 cc/min/1.73m ² , %	4.4	
MMSE, total score	28.3	1.8

MAP=Mean arterial pressure; NSAID=Non-steroidal anti-inflammatory drug; eGFR=estimated glomerular filtration rate, calculated using the 4-variable MDRD equation of Levey et al MMSE=Mini Mental State Examination

Table 2

Coefficients from mixed-effects regression models relating change in 1/Scr with change in cognitive function.

	Test Score	Age	Age*1/Scr ¹	Age*Sex*1/Scr ²
Benton Visual Retention Test	# errors	1.611 **	-0.510 **	-0.165 **
Boston Naming Test	# correct	-1.294	0.488	
CVLT Learning Slope	Mean # of new words per trial	-0.191 **	0.126 **	
CVLT Free recall, short delay	# correct	-1.257 **	0.337	
CVLT Free recall, long delay	# correct	-1.335 **	0.486	
Digit Span Test, forward	# correct	-0.251	-0.020	
Digit Span Test, backward	# correct	-0.247	-0.033	
Category Fluency	# correct	-1.768 **	0.256	
Letter Fluency	# correct	-0.667	0.119	
Trail-Making Test, Part A	Time to completion	6.165 *	1.133	
Trail-Making Test, Part B	Time to completion	19.48 *	6.906	

CVLT = California Verbal Learning Test; SCr = Serum creatinine concentration.

*
p<.05**
p<.01¹
Test of the association of 1/Scr with change in score on cognitive test.²
Test of the interaction between 1/Scr and sex on change in cognitive test score; where blank, no significant (p<.05) interaction detected.

Table 3

Coefficients from mixed-effects regression models relating change in eGFR_{MDRD} with change in cognitive function.

	Test Score	Age	Age*eGFR ¹	Age*Sex*eGFR ²
Benton Visual Retention Test	# errors	1.664**	-0.008**	
Boston Naming Test	# correct	-1.496*	0.011	
CVLT Learning Slope	Mean # of new words per trial	-0.171**	0.002**	
CVLT Free recall, short delay	# correct	-1.338**	0.005*	
CVLT Free recall, long delay	# correct	-1.342**	0.006*	
Digit Span Test, forward	# correct	-0.300	0.0001	
Digit Span Test, backward	# correct	-0.240	-0.001	
Category Fluency	# correct	-1.700**	0.003	
Letter Fluency	# correct	-0.650	0.005	
Trail-Making Test, Part A	Time to completion	7.107**	0.005	-0.037*
Trail-Making Test, Part B	Time to completion	20.436*	0.118	-0.168**

CVLT = California Verbal Learning Test

* p<.05

** p<.01

¹ Test of the association of eGFR with change in score on cognitive test.

² Test of the interaction between eGFR and sex on change in cognitive test score; where blank, no significant (p<.05) interaction detected. A negative coefficient indicates the relationship between